Paladin Advisory Group LLC Sells 4,898 Shares of Pfizer Inc. (NYSE:PFE)

Paladin Advisory Group LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 43.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,496 shares of the biopharmaceutical company’s stock after selling 4,898 shares during the quarter. Paladin Advisory Group LLC’s holdings in Pfizer were worth $187,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Worth Asset Management LLC acquired a new position in Pfizer in the first quarter valued at about $29,000. Briaud Financial Planning Inc acquired a new position in Pfizer in the third quarter valued at about $30,000. GoalVest Advisory LLC grew its stake in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the period. Mizuho Securities Co. Ltd. acquired a new position in Pfizer in the third quarter valued at about $34,000. Finally, VisionPoint Advisory Group LLC grew its stake in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Guggenheim assumed coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Performance

NYSE:PFE traded up $0.60 on Friday, hitting $25.99. The company’s stock had a trading volume of 38,347,117 shares, compared to its average volume of 42,429,016. The firm has a market capitalization of $147.17 billion, a P/E ratio of 72.22, a price-to-earnings-growth ratio of 1.15 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a one year low of $25.23 and a one year high of $40.37. The stock has a fifty day moving average of $27.14 and a two-hundred day moving average of $28.74.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.14 earnings per share. Research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.